BioAtla (NASDAQ:BCAB) Shares Down 1.7% – Time to Sell?

BioAtla, Inc. (NASDAQ:BCAB) traded down 1.7% during mid-day trading on Friday . The company traded as low as $3.89 and last traded at $3.9210. Approximately 6,513 shares changed hands during trading, a decline of 89% from the average session volume of 60,562 shares. The stock had previously closed at $3.99.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Wall Street Zen raised BioAtla to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioAtla has an average rating of “Hold” and a consensus target price of $200.00.

BioAtla Price Performance

The stock has a market capitalization of $6.51 million, a P/E ratio of -0.09 and a beta of 0.76. The stock’s fifty day moving average is $3.83 and its two-hundred day moving average is $8.32.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Friday, May 15th. The company reported ($4.22) EPS for the quarter, beating analysts’ consensus estimates of ($10.00) by $5.78.

Institutional Trading of BioAtla

A number of hedge funds have recently made changes to their positions in the stock. Woodline Partners LP acquired a new stake in shares of BioAtla during the first quarter worth approximately $26,000. ADAR1 Capital Management LLC purchased a new stake in BioAtla in the 4th quarter worth approximately $104,000. Susquehanna International Group LLP lifted its position in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after buying an additional 177,760 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of BioAtla during the 3rd quarter valued at $235,000. Finally, Jane Street Group LLC boosted its stake in shares of BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after buying an additional 123,597 shares during the period. 77.23% of the stock is owned by hedge funds and other institutional investors.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.